



William J. Sandborn, MD

Chief, Division of Gastroenterology and Director, Inflammatory Bowel Disease Center, UC San Diego Health; Professor of Medicine, UC San Diego School of Medicine, San Diego, CA

Dr. William Sandborn is a board-certified gastroenterologist and one of the world's top experts in the management of Crohn's disease and ulcerative colitis. He completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, CA, and a gastroenterology fellowship at the Mayo Clinic in Rochester, MN, in 1993. From 1993 to 2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine; Vice Chairman of the Division of Gastroenterology and Hepatology; and Associate Dean of Research for Intellectual Property and Industry Relations.

In 2011 Dr. Sandborn became a tenured Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center, which unites the expertise of gastroenterologists, radiologists, nutritional health experts, surgeons and digestive disease physician-scientists to deliver comprehensive, innovative care. Since 2021 he has continued as a Professor of Medicine at UCSD and served as the Chief Medical Officer at Shoreline Biosciences.

Dr. Sandborn's research interests are clinical trials and clinical pharmacology related to inflammatory bowel diseases (IBD). He is internationally recognized for his contributions in the fields of biotechnology therapy; clinical pharmacology; conduct of clinical trials, diagnosis and treatment of pouchitis; epidemiology and natural history; and endoscopic and radiographic imaging techniques. His clinical trials have been instrumental to developing modern treatments for IBD, and have set the standard for clinical care. He has led the development of novel medicines and helped to establish holistic care models that have improved patient care and outcomes. Dr. Sandborn is a sought-after clinician, and a mentor to colleagues and students who have gone on to run major IBD centers.

He has published more than 856 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h-index is 140. He is a member of the editorial board for the New England Journal of Medicine.

In 2019, Dr. Sandborn received the Sherman Prize for Excellence in Crohn's and Colitis.

Dr. Sandborn was a co-founder of Santarus (founded 1998, IPO in 2004, acquired by Salix pharmaceuticals in 2013), a member of the board of directors for Prometheus Biosciences (from 2017 until IPO in 2021), and a co-founder of Shoreline Biosciences (founded 2020).